Board
Dr Brad Walsh
CEO and MD
Brad is the founder of GlyTherix. He has a PhD in protein chemistry, led research groups in government agencies, universities and hospitals and has founded three companies. He was joint recipient of the 2015 Eureka Prize, for Interdisciplinary Research. He has co-authored over 120 peer reviewed papers and book chapters and seven patents.
Dr Nat Lenzo
Non-Executive Director
Dr Lenzo is an Acute/General Medicine Physician and Nuclear Medicine Specialist with interests in Molecular Imaging and Radionuclide Therapy. He has been involved in the concept, development and set up of cyclotron facilities in Perth (2) and Jakarta. He set up the first private theranostic facilities in Australia for targeted radionuclide therapy of cancer at Hollywood Private Hospital, Perth and Macquarie University Hospital, Sydney.
David Burdis
Chief Financial Officer / Company Secretary
A seasoned financial professional having worked in chemical, telecommunications and financial services industries. He has held various senior/board positions, for listed and unlisted companies, in Australia, UK and Hong Kong, including GFA International Limited, Swire Blanch Limited and OAMPS Limited.
Mr Raymore Millard
Non-executive Director
Mr Millard is a consultant with extensive experience in providing strategic advice to both listed and unlisted companies in Australia and overseas. He has assisted various companies in raising seed capital and with their ultimate listing. He is similarly assisting the Company.